AbbVie Inc (ABBV)vsRapid Micro Biosystems Inc (RPID)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
RPID
Rapid Micro Biosystems Inc
$1.99
0.00%
HEALTHCARE · Cap: $99.14M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 182598% more annual revenue ($62.82B vs $34.38M). ABBV leads profitability with a 5.8% profit margin vs -145.8%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
RPID
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for RPID.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : RPID
Revenue growth of 11.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : RPID
The primary concerns for RPID are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while RPID is a turnaround play — different risk/reward profiles.
RPID carries more volatility with a beta of 1.46 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Rapid Micro Biosystems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rapid Micro Biosystems Inc (RPID) is an innovative biotechnology company focused on revolutionizing microbiological quality control processes within the pharmaceutical and biotechnology industries. Utilizing state-of-the-art automated growth-based microbial detection technologies, RPID significantly improves the accuracy and efficiency of microbial testing, which is vital for adhering to stringent regulatory standards. As demand for rapid and reliable quality assurance solutions continues to grow, Rapid Micro is well-positioned to drive advancements in testing methodologies that are essential for maintaining product safety and excellence in highly regulated environments.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?